AdvisorShares Psychedelics ETF Rating $17.55 +0.02 (+0.11%) Closing price 08/28/2025 04:10 PM EasternExtended Trading$17.25 -0.30 (-1.70%) As of 08/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.99Holdings in PSIL have an aggregate rating of Moderate Buy based on 80 analyst ratings issued in the past year covering 13 companies (69.9% of the portfolio).PSIL Aggregate Price Target$17.55High Prediction$17.55Average Prediction$17.55Low Prediction$17.55Holdings in PSIL have an aggregate price target of $17.55 and a range of $17.55 to $17.55 covering 13 companies (69.9% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy5 Moderate Buy rating(s)Hold1 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 13 PSIL Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings13.32%ATAIatai Life Sciences$4.65+1.8%3.4694 of 5 stars3.17$11.25 141.9%6Gap Up9.01%MNMDMind Medicine (MindMed)$9.78-0.7%2.6714 of 5 stars3.22$24.71 152.7%9Positive News6.83%CMPSCOMPASS Pathways$4.81+1.9%2.4243 of 5 stars2.86$16.29 238.6%7Positive News5.71%ALKSAlkermes$28.93-1.1%4.6727 of 5 stars2.83$41.08 42.0%125.34%NRXPNRx Pharmaceuticals$2.52-2.3%3.2087 of 5 stars3.20$28.50 1,031.0%55.19%STIMNeuronetics$3.44+2.4%2.1202 of 5 stars3.00$7.00 103.5%15.06%GHRSGH Research$13.84+1.5%2.2843 of 5 stars2.88$32.00 131.2%8Upcoming Earnings4.82%NBIXNeurocrine Biosciences$138.94+0.6%4.8969 of 5 stars2.86$159.50 14.8%21Positive News4.57%VTGNVistaGen Therapeutics$3.23+1.6%1.2877 of 5 stars3.001Positive News4.32%NEUPNeuphoria Therapeutics$12.21+19.5%2.0101 of 5 stars3.00$21.00 72.0%1News CoverageAnalyst ForecastAnalyst RevisionHigh Trading Volume2.86%SUPNSupernus Pharmaceuticals$45.37+0.7%2.1089 of 5 stars2.50$41.00 -9.6%4Positive NewsInsider Trade1.96%RLMDRelmada Therapeutics$0.78+15.8%4.6366 of 5 stars2.25$5.00 545.2%4Positive NewsHigh Trading Volume0.88%ENVBEnveric Biosciences$1.26-13.1%2.4058 of 5 stars3.00$10.00 693.7%1News CoveragePositive NewsHigh Trading Volume This page (NYSEARCA:PSIL) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access